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Résumé
Les maladies cardiaques sont une des principales causes de mortalité en Amérique du
Nord. Parmi les facteurs de risque impliqués, l’hypertrophie du ventricule gauche (UVG)
est un des facteurs indépendant de prédiction de la mortalité et morbidité liées aux
maladies cardiaques. Plusieurs expériences ont mis en évidence les effets anti-
hypertrophique du Peptide Natriurétique Atrial (ANP), et de sa voie de signalisation. En
se liant à son récepteur, le Guanylyl Cyclase-A (GC-A), I’ANP augmente la
concentration cellulaire de GMPc. Afin de mieux comprendre l’effet anti-hypertrophique
de l’ANP et de son effecteur, le GMPc, notre laboratoire a créé une souris transgénique
qui surexprime de façon constitutive le domaine catalytique du GC-A au niveau des
cardiomyocytes. Ces souris sont protégées contre l’hypertrophie induite
expérimentalement. Plusieurs cibles cytosoliques du GMPc ont déjà été identifiées.
Cependant, très peu est connu sur ses effets au niveau de la transcription des gènes dans
les cardiomyocytes. Au cours de ce travail, j’ai utilisé la technologie Afi’metrix pour
investiguer l’effet du GMPc sur la transcription génique des souris GC-A en les
comparant à celles de type sauvage. Les données indiquent l’augmentation de
l’expression, dans les souris transgéniques, d’un groupe de gènes qui sont la cible de la
cytokine pro-inflammatoire interféron-gamma (IFNy) ainsi que 1’ IFNy lui-même. Des
études subséquentes avec des souris déficientes en IFNy ont suggéré que l’IFNy peut
jouer un rôle dans la régulation de l’expression de l’ANP. Ces expériences suggèrent que
les cytokines pro-inflammatoires jouent un rôle dynamique dans la réponse cardiaque au
stress.
oiv
Abstract
Cardiac diseases are one of the principal causes of mortality in North America.
Among the many risk factors implicated, left ventricular hypertrophy (LVH) has
been shown to be an independent predictor of cardiac mortality and morbidity.
Several unes of evidence indicate that Atrial Natriuretic Peptide (ANP), and its
signalling pathway, has anti-hypertrophic effects on the heart. The binding of
ANP to its receptor, Guanylyl Cyclase-A (GC-A), increases the cellular
concentration of cGMP. In order to investigate the downstream anti-hypertrophic
effects of cGMP on cardiomyocytes in vivo, our laboratory has created a
transgenic mouse that overexpresses a constitutively active catalytic fragment of
the GC-A receptor exclusively at the level of cardiomyocytes. These mice are
protected against the effects of experimentally induced forms of cardiac
hypertrophy. Although several cytosolic targets of cGMP have been identified,
little is known about its effects on gene transcription in cardiomyocytes. In these
experiments, I have investigated the effect of cGMP on transcription by
comparing gene expression of the GC-A transgenic mice with wild type mice
using affymetrix teclmology. This revealed that a number of Interferon-gamma
(IFN’)-activated genes, as welY as IFNy itse1f are upregulated in these mice.
further studies using IFNy KO mice suggest a role of IFNy in the regulation of
ANP expression. These experiments suggest a dynamic role of pro-inflammatory
cytokines in the cardiac response to stress.
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1Introduction
Cardiac diseases
The heart primarily functions to circulate oxygen to the tissues of the body
at a rhythm that meets the metabolic demands of its cellular components.
Continuai biomechanical stress placed on the heart can induce changes
within the myocytes that iead to inadequate pumping and uitimately to
cardiac diseases, one 0f the major causes of morbidity and mortality in
North America (1). Left ventricuiar hypertrophy (LVH) has emerged in
recent years as an independent risk factor for morbidity and mortality
linked to cardiac diseases and has therefore become an important
predictor of disease outcome (2). LVH is characterized by the overgrowth
or excessive deveiopment of the Ieft ventricle (LV). it is multifactorai in
nature; primary risk factors include underiying disease state
(hypertension, diabetes, hyperthyroidism, obesity) and lifestyle choices
(sedentariness, diet, consumption of aicohoi or tobacco) (3-7). in addition,
disease pathogenesis is infiuenced by multiple genetic susceptibility loci
which account for 60-70% of the variabiiity (8).
LVH can be spiit into two broad categories. The first is concentric LVH,
seen in pressure-overioad induced hypertensive states. The second,
eccentric LVH, is induced by voiume-overload and is typically seen in
valve dysfunction (9). At a cellular ievei, LVH is characterized Iargeiy by
o
2an increase in ceIl volume, as seen under the light microscope, rather
than number of celis due to division (10).
It is generally believed that LVH develops to preserve contractile function
when cardiac workload is chronically increased. Development of LVH is
thus viewed as beneficial, at least in the short term, as it allows the heart
to deal with an increasing demand for contractile power (11, 12).
However, when LVH continues for an extended period of time, it can
become maladaptive, and lead to dilated cardiomyopathy, heart failure
and sudden death (13, 14).
As LVH is one of the most powerful independent risk factors for cardiac
disease (3), understanding the pathways that cause or prevent LVH is
important to improve treatment of these diseases. Recent work from our
laboratory has focused on the identification of genetic loci associated with
reduced LVH. This has led to the identification of the atrial natriuretic
peptide (ANP) pathway as an important modulator 0f LVH. In this chapter,
I will thus describe briefly the pathways that are involved in causing LVH
and give an overview of molecules involved in its prevention. Then I will
describe in detail the ANP signalling pathway, which has been extensively
implicated in the prevention of LVH and 5 0f particular interest to my
project.
o
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Left ventricular hypertrophy
Ca2 signalling in the heart
Ca2 handiing plays a pivotai roie in catdiac homeostasis. It is the key
signalling molecule invoived in initiating myocyte contraction and thus,
changes in its signaiiing orchestrate a vast number of cardiac adaptations
such as ceilular growth and strength of contraction (15). Activation 0f
myocardiai contraction begins with an action potential that depolarizes the
myocyte celi membrane and activates L-type voltage operated channeis
(L-type VOC) (16). This aiiows a small puise 0f Ca2 to enter the ceil and
activate a ciuster of four to six ryanodine receptors (RyR) which release a
spike of sarcopiasmic reticulum (SR) Ca2 (16). The Ca2 generated from
this action wiII then activate the contraction of nearby sarcomeres. The
signai is terminated when Ca2 is rapidiy removed from the cytoplasm by
ionic pumps such as sarco(endo)plasmic reticulum Ca2tATPase 2
(SERCA2) in the sarcoplasmic reticulum and NaICa2 exchangers in the
plasma membrane (15). Cytoplasmic Ca2 is aiso taken up by the
mitrochondria via the mitochondriai Ca2 uniporter, which stimulates them
to produce ATP, thus ensuring that there is enough energy to sustain the
contraction (15, 17).
Influx and efflux of Ca2 are tightly controiied in cardiac celis such that
there is no net loss or gain 0f Ca2 in either the SR or the extracellular
milieu. This is of special importance due to the large flux of Ca2 at every
(J beat of the heart. Considering the tight regulation over the amount of
4o
Figure 1.1 Mechanisms 0f cGMP-dependant protein kinase (PKG)action on
Hypertrophic signalling. (PL) phospholamban, (AC) adenylate cyclase, (DAG)
Diacylglycerol, (EP) epinephrine, (NE) norepinephrine
Ca2 released into the cytoplasm, modifications 0f the amplitude 0f a
contraction are made possible by modulating SR Ca2 release (15). This
is achieved by signalling pathways such as norepinephrine and their f3-
adenergic receptors that are activated to modulate cardiomyocyte reaction
to increased cardiac demand (18).
Hypertrophic stimuli
Hypertrophic signalling is intimately related to changes in Ca2 signalling
(Figure 1.1). A rise in the amount 0f Ca2 released from the SR wiII not
only increase the extent to which a cardiac fibre contracts but also has an
o
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effect on basal transcriptional and transiational levels of the individual
myocytes (15).
LVH is triggered by two major types of input: 1) mechanical stress and 2)
neural or humoral factors. Hypertrophy triggered by mechanical stress
involves the activation of stretch-activated ion channels (19). Details on
how this signal is mediated remain unclear but these channels likely
promote their effects through changes in intracellular Ca2 concentration.
Furthermore, mechanical stress can activate the expression of neural and
humoral factors involved in hypertrophy. A wide variety of neural and
humoral factors have been implicated in activating hypertrophic signais
(13). These factors include vasoactive peptides, catacholamines, growth
factors (GF5), cytokines and hormones (13, 19). Ultimately, these
pathways work toward increasing the basal amount of SR Ca2 released,
transcription of cardiac growth related genes, and an increased capacity
for the translation of these newly transcribed mRNA targets (figure 1 .1).
Several vasoactive peptides and catecholamines induce hypertrophy as a
consequence of their role in increasing the contractility of the cardiac
muscle. Catecholamines such as noradrenaline modulate cardiomyocyte
Ca2 signalling through activation of G-protein coupled receptors (GPCR)
linked to an adenlylate cyclase, resulting the activation of PKA (18, 19).
PKA phosphorylates L-type VOC and RYR2, increasing their ability to
release Ca2 into the cytosol (20, 21). Another effect of PKA is the
() inactivation of phospholamban (PLN), a negative regulator of
o6
(22). This permits an increase in the concentration of Ca2 in the SR, and
thus allows more Ca2 to be released upon each contraction.
A second pathway leading to increased SR Ca2 release is activated by
vasoactive peptides such as angiotensin Il (ANGII) and endothelin. These
molecules activate a GPCR coupled to phospholipase C (PLC). Activation
of PLC resuits in an increase of 1P3 which will stimulate SR Ca2 release
by the 1P3 receptor (IP3R) (23).
Transcriptional effects of hypertrophic stimuli
An increase in Ca2 not only boosts the strength of cardiac fibre
contraction, but also has an effect on transcription. Free Ca2 can bind to
Calmodulin (CaM), evoking the activation of a phosphatase called
calcineurin (24). One of calcineurin’s functions is to activate the
transcription factor Nuclear Factor of Activated T-CeIIs (NFAT) (25).
Calcineurin and NFAT play a prominent role in hypertrophic responses.
For instance, transgenic models that overexpress of calcineurin, or a
constitutively active nuclear form of NFAT, lead to cardiac enlargement
(26). Ca2 is also able to activate Ca2I CaM-dependent kinase Il (CaMKII)
which translocates to the nucleus and phosphorylates class Il Histone
Deacetylases. This wiII remove them from the nucleus and allow
transcriptional activity of myocyte enhancer factor-2 (27). The importance
of these proteins in hypertrophy have also been demonstrated using
animal models (28-3 1).
7In addition to these effects on Ca2 homeostasis, some hypertrophic
stimuli such as growth factors can activate cardiac ceil growth through
activation of MAPK cascades (13). A third effect of hypertrophic stimuli is
the regulation of translation through activation of Phosphatidylinositol-3-
Kinase (PI3K) by 3- and Œ- adenergic receptors as well as IGF-1(32-34).
PI3K’s main cellular mediator is protein kinase B (PKB). PKB activates
p7OS6 kinase and mammalian target of rapamycin which increases
cellular translation via the 56 subunit of the translational machinery. PKB
also phosphorylates glycogen synthase kinase (GSK3) thereby
inactivating it (35). This inactivation event has two roles; first, GSK3
inactjvates transcription factors involved in cardiac growth, such as
NFAT3 (36) and GATA4 (37), by promoting their export from the nucleus.
Second, GSK3 phosphorylates eukaryotic initiation factor 2B, inhibiting
protein translation (38). Hence the inactivation of GSK3 will enhance both
transcription and translation.
Changes in gene expression and protein activation induced by
hypertrophic stimuli lead ultimately to cellular growth in the absence of
cellular division (19). At the molecular level, the first changes seen within
celis are a rapid, yet transient, activation 0f what is known as the
“immediate early genes” (c-fos, c-jun, c-myc, egr-1, and HSP7O). These
genes are normally implicated in the regulation of celI cycle and
proliferation. However, as cardiomyocytes are terminally differentiated
cells, these factors will signal celI growth rather than ceil division (10, 19).
$Following this initial response, there is a te-induction of the cardiac “foetal
C ‘,..gene program which ncludes 3-myosin heavy chain, a-skeletal actin, as
weII as ANP and B-type natriuretic peptide (BNP). Other changes include
an upregulation 0f constitutively expressed contractile proteins such as
cardiac muscle a-actin and ventricular myosin light-chain-2 (39). AIso
accompanying LVH is a decrease in the expression of the sarco
endoplasmic reticulum Ca2-ATPase 2a (SERCA2a) (40). These ptoteins
have been widely used as biomarkers for deciphering hypertrophic celis
from regular cellular growth(10, 19).
How exactly these changes in expression affect celis and bring about
hypertrophy is not completely clear. In fact, among the biomarkers of
myocardial hypertrophy are factors and signalling pathways, such as
ANP, equally implicated in the negative regulation of hypertrophic effects.
Other pathways implicated in the negative regulation of hypertrophy are
nitric oxide (NO) and bradykinin.
NO and ANP: anti-hypertrophic signalling modules
Nitric oxide (NO) is synthesized from L-arginine by one of three nitric
oxide synthases (NOS) isoforms (endothelial (eNOS), inducible (iNOS)
and neuronal (nNOS)) ail of which are found in the heart and can inhibit
cellular growth in several different types of cells. NO modulates a large
variety of physiological functions among which are regulation of vascular
Û
9tone, neurotransmission, immune ceil mediated cytotoxicity, as well as
contractility of cardiac muscle (41).
In addition, accumulating evidence suggests an anti-hypertrophic role for
NO. For example, TG mice which overexpress eNOS in vascular
endothelial celis are hypotensive and protected from LVH (42). Other
evidence that NO plays a role in protection from cardiac myocyte
hypertrophy was given by experiments on the bradykinin pathway, which
activates the cellular production of NO. These experiments showed that
the bradykinin-NO pathway has a role in protecting cardiac myocytes from
hypertrophic stimuli in rat cardiomyocytes (43). This protective effect of
bradykinin appears to be the consequence of stimulation of NOS (and
thus, production of NO) in endothelial ceNs (44). Knock-out (KO) of the
bradykinin receptor promotes development 0f cardiac hypertrophy in vivo
(45). More recent experiments have shown that bradykinin can also
prevent acute hypertrophic responses in isolated perfused rat hearts, and
this was shown to be accompanied by a significant increase in LV cyclic
GMP (cGMP) (46). One 0f the downstream effectors of NO is cGMP,
which results from the stimulation of soluble guanylyl cyclases (GCs).
A second protective factor is ANP, which also mediates its effects through
induction of cGMP. ANP activates a second type of GC, membrane bound
guanylyl cyclase receptors (GCRs). Abundant evidence indicates that
cGMP can act as a anti-hypertrophic agent. For instance, a synthetic
analog of cGMP (8bromo-cGMP) has been shown to prevent hypertrophy
10
Q in cultured rat cardiac myocytes (47). In addition, ANP (and/or its second
messenger cGMP) blocks the hypertrophic response of cultured neonatal
cardiomyocytes and aduit rat cardiomyocytes in vitro. (47, 48).
The natriuretic peptides
ANP is a member of a family of peptide hormones called the natriuretic
peptides (NPs) that are involved in the regulation of blood volume and
blood pressure by direct effects on the kidney and systemic vasculature
(49) (see figure 1.2). Other family members include BNP and C-type
natriuretic peptide (CNP). Although ail of these peptides are referred to as
“natriuretic peptides” because of their relationship to ANP and its function
in the regulation of sodium excretion (natriuresis), they possess other
activities. In fact, CNP has no known natriuretic role as it is primarily
produced by vascular endothelial cells and the central nervous system
(but not by cardiomyocytes), and is involved in fleurai regulation as well
as control of vascular tone (50, 51). The other two NPs, ANP and BNP,
reduce blood pressure by promoting sait and water excretion in the kidney
(52), thereby decreasing blood volume. They also antagonize the renin
angiotensin-aldosterone system, a principal mediator of vasoconstriction,
sodium retention and cellular proliferation. These peptides reduce plasma
renin, ANG II (the end product of the renin system), and aldosterone
secretion (53, 54).
e
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A distinct role for each NP
C
ANP can affect blood pressure by relaxing the vascular smooth muscle
cells (VSMC5) of arterial walls, whereas CNP will relax mostly those of the
veins (55). Although BNP has similar vasorelaxing properties as ANP, its
plasma concentrations are much lower than that of ANP (49, 56).
Furthermore, it has a lower affinity for their shared receptor, guanylyl
cyclase-A (GC-A) (56). lndeed, it has been suggested that BNP may have
another yet undiscovered receptor, due to the tact that GC-A KO mice
retain a high affinity for cGMP responses to BNP in tissues such as the
adrenal gland and testis, and these binding properties are flot due to any
other known guanylyl cyclase receptor (GCR) (57). In fact, the phenotype
cf the BNP KO mice indicates that BNP might have a function distinct
from that cf ANP. These mice do not have hypertension nor hypertrophy
(as observed in the ANP KO), but display extensive cardiac fibrosis (58).
This suggests that the main role of BNP may possibly be that of a
paracrine antifibrotic factor. A distinct role for BNP is also suggested by
the tact that it has less potent vasorelaxing properties than ANP (56). The
autocrine/paracrine role played by ANP in the heart inhibits cardiomyocyte
growth and stimulates diastolic relaxation (59).
Natriuretic peptides have the ability to regulate celI growth and
proliferation (60-64). 0f particular interest, this has been shown for
vascular smooth muscle cells (65), cardiomyocytes (66) and cardiac
tibroblasts (67). The antiproliferative effects of NP5 can be mimicked by 8-
12
bromo-cyclic GMP (66). Some data suggest that the growth inhibiting
effects of cGMP, ANP and NO in cardiac myocytes and fibroblasts are
mediated in part by the inhibition of Ca2 influx (47).
Expression ofANP and BNP
In healthy aduits, ANP and BNP are predominantly produced in atria,
stored in atrial granules as precursor prohormones, and secreted by atrial
myocytes (68, 69). ANP is aiso present in the ventricies of the developing
embryo and foetus, but its ventricular expression declines rapidiy during
the perinatal period (70). BNP is also present in the early stages of
cardiac morphogenesis (71), but the decline in ventricular expression of
BNP in aduits is not as pronounced as that 0f ANP (49). Indeed,
ventricular expression of BNP continues throughout aduithood. The main
trigger for the cardiac production and release of ANP is an increase in wall
stretch and pressure (72). BNP secretion is however a reflection of LV
overload (73).
Synthesis ofANP
Ail three NPs are synthesized and stored as precursor prohormones and
contain a core structure which includes a highiy conserved internai
sequence of CFGXXXDRIXXSGLGC (54). This sequence produces a ring
structure through the formation of a disuifide bond between two cysteine
residues, which is necessary for receptor recognition and biologicai
function (74).
ANP CNP
/BNP\/
GC-A NPR-C GC-B
GTP PDEs GTP
cGM
PKG
Regulation of Substrate Protein
Ion channels Phosphorylation
Gene expression
Figure 1.2 The Natriuretic Peptide Family Signalling Pathway.
ANP preprohormone is composed of 151 amino acids. From this, the N-
terminus is removed in the endoplasmic reticulum, leaving a 126 amino
acids prohormone ANP for storage in granules in the atrial
cardiomyocytes (54). Once released, pro-ANP is converted to the
biologically active ANP by proteolytic cleavage. This cleavage is a critical
step in the regulation of ANP activity and produces the biologically active
fragment from the Carboxyl-terminal (C-terminal) end of the fragment (75).
The processed peptide of ANP is also known as atrial natriuretic factor.
Processing is similar for BNP and CNP (54). One of the serine proteases
shown to have the ability to convert pro-ANP into ANP is Corin (76) (atrial
natriuretic peptide-converting enzyme, pro-ANP converting enzyme, heart
14
Q specific serine protease ATC, LDC receptor-related protein). Corin, is a
cardiac specific serine protease. The cleavage in pro-ANP by corin is
highly sequence specific (76).
NP receptors
ANP can bind to the GC-A receptor, which is thought to be the main
functional receptor for ANP (figure 1.2). The other ANP receptor is the
natriuretic peptide receptor C (NPR-C), whose main function is the
clearance of NPs and wiII be described below. Both receptors are found in
myocardium and fibroblasts (77, 78). GC-A is part of a family of receptors
which also include the receptor for CNP (GC-B;NPR-B), a receptor for
bacterial heat stable enterotoxins involved in the uptake 0f water and sait
in the intestine as weil as epithelial ceil growth and differentiation (CC-C)
and finally the orphan receptors Guanylyl Cyclase-D, E, F and G (79-8 1).
These latter mentioned receptors are implicated in the senses of smell
and sight (82).
As stated above, CC-A is preferentially activated by ANP and BNP,
whereas CNP activates GC-B. BNP is known to interact with the CC-A
receptor, but evidence indicates that it may activate another unknown
receptor. Indeed, the amino acid sequence of BNP is different among
species (human, rat and mice) and some tissues of the CC-A Knock out
mice retain significantly high affinity cCMP responses to BNP (57, 82). To
G
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date, the identity of that putative alternative BNP receptor has not been
L
elucidated yet.
Structure of the GC receptors
AIl of the GCRs are coupled to a cytoplasmic C-terminal guanylyl cyclase
catalytic domain and signal via formation of cGMP. GCRs are single
transmembrane proteins consisting of a single extracellular domain, a
transmembrane domain and two intracellular domains separated by a
hinge (82). Glycosylation of the residues located at the N-terminal end of
the 440 amino acid extracellular domains of GCRs are common in aIl
GCRs except GC-F, although functional consequences of this remain
controversial (83). It is possible that glycosylation plays a role in ligand
binding, folding and/or transport 0f particulate GC5 to the membrane.
However, in the case 0f ANP, enzymatic deglycosylation has had no
significant effect on ANP binding (84). There have also been reports of
tissue specific glycosylation of GC-A but no known function has yet been
determined (85). AIl Membrane GCR5 contain two intracellular domains:
the kinase homology domain and the guanylyl cyclase domain. The
kinase homology domain of approximately 250 amino acids immediately
follows the transmembrane domain and is believed to modulate the
enzymatic activity 0f the C-terminal guanylyl cyclase domain (82, 86). It
contains six residues that can be phophorylated in the intracellular
juxtamembrane region which are in close proximity to a putative ATP
C binding site (87). Phosphorylation of the kinase homology domain is
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required for receptor activation (88). This putative ATP binding domain
contains a consensus ATP binding motif found in many protein kinases.
No kinase activity, however, has been detected. Although ATP is required
for maximal NP-dependent activation (89), and the putative ATP binding
site in the kinase homology domain is suspected for its binding, the exact
location of ATP binding has not been solidly determined possibly because
the association of ATP to the receptor is too loose to obtain positive
binding or cross-linking results (90).
The kinase homology domain is separated from the 250 aa Guanylyl
cyclase C-terminal domain by a 41 aa amphipathic coiled-coil hinge
region that is involved in higher order oligomerization (91). Formation of
homodimers or homotetramers is essential for the activation of the
catalytic domain of CC-A and CC-B (92).
The proposed model for activation of the CC-A receptor is that in the
absence of NP, the receptor exists as a homodimer or homotetramer that
is highly phosphorylated and guanylyl cyclase activity is tightly repressed
(90) ANP presumably facilitates ATP binding to the kinase homology
domain, leading to a conformational change in the hinge region of the
receptor (89, 90, 93). This allows the removal of the inhibitory effect of the
kinase homology domain on the guanylyl cyclase domain, leading to their
association and activation (90). This is followed by an increase in the
disassociation of ANP from the receptor and a conformational change in
the kinase homology domain to increase susceptibility to phosphatases,
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thereby inactivating the receptor and decreasing its sensitivity to further
stimulation by ANP (90).
Elimination
Elimination of the natriuretic peptides from circulation is known to occur by
two mechanisms; First, metabolism by an enzyme called neutral
endopeptidase, which is mostly found in the brush border of the proximal
convoluted tubule of the kidney and also in lungs, intestine, seminal
vesicies and neutrophiles and second by cellular internalization after
binding to a specific clearance receptor NPR-C (94, 95).
NPR-C
NPR-C is a subclass of GCRs which iacks both intracellular domains.
lnstead, it has a 37aa intracellular domain that shares homology with
neither GC-A nor GC-B (96). As stated above, this receptor is capable of
internalizing ail of the NPs (ANP,BNP and CNP) and delivers them to
lysosomes for degradation. NPR-C, in the case of renai action, was
considered to be biologicaily silent. Thus, its proposed function was the
sequestration and metabolic clearance of ANP (95). However, ANP was
shown to inhibit cAMP production in cuitured thyroid cells, which
exclusively express NPR-C. This suggested that NPR-C might also have
some signalling properties (97). It has since been reported that ANP
mediates inhibition of adenylyl cyclase activity in the heart and aorta of
__
spontaneous hypertensive rats and human hypertensive patients (98, 99).
‘s
A synthetic peptide containing the 37aa intracellular domain of NPR-C has
been shown to inhibit adenylyl cyclase activity in cardiac muscle
membranes (100). This inhibition of adenylyl cyclase activity may possibly
explain some of the hypertrophic actions 0f ANP. However, it is not known
whether NPR-C plays any role in cardiac hypertrophy.
Downstream targets of cGMP
Effects cf the membrane GCRs are presumably ail mediated by the
synthesis of cGMP as an intracellular signalling molecule, which then
modulates the activity of specific target proteins. One 0f these targets is
Phosphodiesterases (PDE), which are involved in the degradation 0f
cGMP and cAMP (41). It is thought that changes in PDE activity due to
activation by cGMP, alter cAMP and cGMP levels by increasing or
decreasing them, depending on the type 0f PDE expressed in the ceil
(101). Another PKG target is the cGMP gated nucleotide channels which
are essential for signal generation in sensory organs (102).
However, the major mediator of cGMP action in the celI is thought to be
Protein Kinase G (PKG) (103, 104). There are two different PKG genes
known to modulate different physiological functions of cGMP, PKGI and Il.
PKG I has two isoforms, la and l; la being the only PKG found in the
heart (105). PKGIa exists in the cytosol as homodimers bound together
and kept inactive by the N-terminal domains of the individual PKG
proteins (102). Once activated, PKG phosphorylates target proteins in the
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cytosol. In general, the action of PKG has been best elucidated in smooth
muscle ceils (SMCs) where it is involved in muscle relaxation. In these
cells, activated PKG phosphorylates ion channeis, pumps, receptors and
enzymes, resuiting in a decrease in intracellular Ca2 as weII as sensitivity
to Ca2 signais (106) (see figure 1.1).
PKG and Ca2 signalling
Among the ion channeis affected by PKG in the plasma membrane are
maxiK potassium channels, L-type VOC and the Ca2+ ATPase pump.
MaxiK channels are activated by Ca2 and allow the efflux of potassium
from a celi. This hyperpolarizes the plasma membrane and causes the
ciosure of L-type VOC, thus inhibitïng Ca2 entry into the cell (107).
Blocking maxiK channels using the specific inhibitor iberiotoxin partially
inhibits cGMP-induced SMC relaxation (108). There exists some evidence
that PKG can directly phosphorylate L-type VOC, leading to decreased
Ca2 entry and SMC relaxation (109). However, PKG’s direct involvement
in the modification of L-type VOC activity is not yet compietely clear. In
addition, it has been suggested that PKG may influence increased Ca2
export from the cell via the indirect activation of the Ca2 ATPase pump,
through either an intermediate protein or the generation of phosphatidyl
inositol-4 phosphate (106).
PKG’s effect on the uptake of cytosolic Ca2 by the SR is believed to be
carried out by changes in SERCA2 and IP3R activity. At the level of the
G
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SR, phosphorylation of phospholamban by PKG results in an increase in
SERCA2 activity (110). In addition, PKG phosphorylation reduces IP3R
activity both directly (111), and through the activation of the negative
regulator of IP3R, IP3R-associated cGKI protein (41, 112). A more indirect
effect of PKG on cytosolic Ca2 is also carried out thought inhibition of 1P3
synthesis. It is however unclear whether the mechanism for this effect is
through inhibition of GCPR or PLC (41).
Effects of PKG on the contractile machinery
Another effect of PKG leading to SMC relaxation is the decrease in
sensitivity cf the contractile machinery to Ca2 (106). Muscle contraction is
dependent on the phosphorylation of myosin light chain (MLC) by MLC
kinase (MLCK), this being triggered by a rise in cytosolic Ca2.
Desensitization by PKG is achieved through the inhibition cf MLCK and
the activation of myosin phosphatase (MP), which dephosphorylates MLC.
This is thought to occur indirectly through the inactivation of Rho, a small
G-protein which activates MLCK and represses MP to facilitate
contraction (41). Direct phosphorylation of MP by PKG may also Iead to
its activation (113). Modification cf the cytoskeletal architecture of SMC by
PKG has also been proposed in Ca2 desensitization through the Heat
shock protein 20 (HSP2O) (114, 115) which is a proposed regulatory
component cf the actin-based cytoskeleton. Induction of PKG in
cardiomyocytes also leads a reduction in Ca2 signalling and ceil
C
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contractility. PKG targets in cardiomyocytes include L-type VOC as weIl
as troponin T which regulates actin/myosin interactions (116).
Effects of PKG on gene expression
In addition to its effects on muscle contractility, PKG has been shown to
modulate gene expression. For example, PKG can reduce the expression
of several hypertrophic biomarkers in cardiomyocytes following
hypertrophic stimuli (117). This could be achieved through at least three
mechanisms (figure 1.1). First, the phosphorylation of several ion
channels and pumps by PKG will decrease CaM-dependent activation of
calcineurin, thereby maintaining NFAT inactive in the cytosol (118). PKG
can also affect the Rho dependent activation of serum response factor by
inhibiting the activation of Rho downstream of growth factor receptors and
GPCR (104). Finally, PKG is capable of increasing NF-kB DNA-binding
activity both directly by phosphorylation of the NE-kB subunits p50 and
p65 as well as indirectly through the phosphorylation and subsequent
degradation of the NE-kB inhibitor 1kB-a (119). This has been linked to
expression of TNF-Œ in cardiomyocytes (119). In addition, several other
pro- and anti-proliferative pathways have been shown to be modulated by
the various PKG isoforms in various tissues (117).
Disease state
Under normal conditions, ANP is expressed and released from the atria of
the heart in response to stretch and pressure. However, under several
22
pathological conditions, ventricular myocytes may undergo phenotypic
modifications allowing them to produce ANP and secrete them into
circulation as weIl (120, 121). Concentrations of both BNP and ANP were
shown to increase in proportion to the severity of Ieft ventricular
dysfunction. This release cf ANP was originally thought to exert its effect
on blood pressure and blood volume. However, information derived from
several transgenic (TG) and knockout (KO) animal models have made it
clear that ANP (but not BNP) can regulate cardiac mass via a direct action
on cardiac celis (as outlined in Table 1.1).
In vitro evidence for a role ofANP in preventing hypertrophy
Originally, studies using animal KO models had shown that deficiency in
ANP or GC-A lead to an increase in blood pressure as well as cardiac
mass. At first, this increase in mass was thought to be a consequence of
the increased blood pressure of these animaIs (122-124). In vitro
evidence has since emerged supporting a role for ANP in the regulation of
the hypertrophic response. ANP (as well as its second messenger cGMP)
can block the effects of hypertrophic stimuli in rat neonatal
cardiomyocytes (47, 48). In these conditions, a GC-NGC-B inhibitor (HS
142-1) was able to block the anti-hypertrophic effect of ANP, suggesting
that the anti-hypertrophic effect of ANP is mediated through activation of
its receptor (48). Further investigation conducted on aduit rat
cardiomyocytes (which presumably resemble more cardiomyocytes found
in the heart of aduit animais) Ied to similar conclusions (66).
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Gene Type of
. Characteristics Ref.targeted targeting
- Increased HW/BW
- Increased blood pressure with increasing dietary sait (122,
ANP KO intake 125, 126)
- Exagerated response to TAC, including increase in
HW/BW ratios
- Increased Biood pressure that is resistant te changes in
sait concentration
- Increased HW/BW throughout post-natal life, and
KO
independent of blood pressure (when controlled by drugs) 12.7
- Exaggerated response to TAC; including increase in 128)
HW/BW ratios and increase in chamber dilation, decrease
in cardiovascular function
- Decreased survival
GC A
- Slightly hypotensive animais
KO HS
- Increase in HW/BW (59)
- Decrease in cardiovascular function after TAC
- Exaggerated HW/BW in response te TAC
TG HS
- Decreased HW/BW (129)
- No difference in blood pressure
KO - No difference in HW/BW compared to GC-A KO
X - No difference in blood pressure compared to CC-A KO (129)
TG HS - Decreased cardiomyocyte area compared to CC-A KO
Tabiel.1 Animal Models in the ANP signailing pathway. (HS) heart specific, (TAC)
transverse aortic constriction, (HW) heart weight, (8W) body weight, (TC) transgenic.
Animal models
In addition to these in vitro studies, experiments using mice with deletion
of the gene coding for ANP (Nppa KO) have revealed that when these
mice are fed an extremely Iow sait diet (0.05% NaCi and 0.7% Ca2j, they
have a significant increase in heart weight compared to that of wiid type
counterparts (125). This change in cardiac mass appears to be
independent 0f biood pressure. Another group of investigators have
shown that CC-A deficient mice resuit in animais with eniarged hearts
C
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from the time of birth. This indicated that heart size is iikely to be
independent cf blood pressure, since biood pressure in utero is iargeiy
controlled by the mother (128). in addition, experimentai induction of
pressure overioad through transverse aortic constrictions (TAC) in these
GC-A KO mice leU to increased hypertrophy as compared to wild-type
animais. Such differences were stili observed even when a wide variety cf
anti-hypertensive drugs were used in order to control blood pressure. This
indicates that the sensitivity of these mice to cardiac hypertrophy is
independent of their blood pressure (128). In another study of interest,
CC-A was inactivated specificaiiy in the heart using the LoxP/Cre
recombination system. These mice have a siightiy iower biood pressure
than their fioxed CC-A lillermates, along with a significant increase in the
heart weight / body weight (HW/BW) ratio (59). One iast animal model
worth mentioning is an animal created by the Kishimoto group. This
mouse was created by crossing a GC-A deficient mouse with a TG mouse
overexpressing CC-A specificaiiy in the cardiac myocytes. This resulted in
a mouse une which expressed GC-A solely and specificaiiy in the heart
(129). This group showed that the CC-A transgene expressed within the
cardiac myocyte was insufficient to significanfly Iower blood pressures of
either wiid type or CC-A KO mice (129). The transgene did however, have
a significant effect on iowering cardiomyocyte size. Thus, mounting
evidence points to ANP playing a roie in the reguiation of cardiac mass.
G
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Project background
Previous studies in our Iaboratory have revealed that the cardiac mass in
Wistar Kyoto hyperactive rats (WKHA) is 10% higher than that in Wistar
Kyoto rats (WKY) and that the concentration of left ventricular ANP is
inversely correlated to heart size (130). This difference in size is
independent of blood pressure as both strains have similar blood
pressures (130). Generation 0f a F2 progeny resulting from the cross of
WKY and WKHA rats was thus used in order to map qualitative trait loci
(QTL) linked to both ANP ventricular concentration and cardiac mass.
Resuits from these studies revealed that QTLs overlapping the Nppa
locus on rat norvegius chromosome 5 (RNO5) were Iinked to both traits.
Moreover, sequence analysis 0f the 650 nucleotides upstream of the
Nppa gene that make up the minimal promoter revealed two single
nucleotide polymorphisms (SNP5). One of these 2 substitutions was
shown to reduce significantly the transcriptional activity of the minimal
promoter (131). Lastly, these changes in sequence bring about changes
in ANP concentrations that make functional sense. Evidence that ANP
could possibly protect the heart from hypertrophic stimui was, at the time,
just starting to surface. Taken together, these result suggested that
naturally-occurring polymorphisms that Iead to decreased ventricular
expression of ANP can be associated with increases in Ieft ventricular
mass.
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As a follow-up to these studies, our Iab created a transgenic mouse model
C ...that overexpressed specifically in the heart a constitutively active guanylyl
cyclase domain from the GC-A receptor (GC-Transgenic). These mice
showed an increase in cytosolic guanylyl cyclase activity 0f about 4 fold
compared to their non-transgenic counterparts and a 2.2 fold increase in
cGMP concentrations. Under normal conditions, no differences were
found between the GC-Transgenic mice and their WT littermates for the
HW/BW ratios, nor any other physiological/morphological parameters
considered. However, when challenged with an stress such as
Isoproterenol fa well known model of induced cardiac hypertrophy without
systolic hypertension f132)) or abdominal aortic constriction (AAC), the
transgenic hearts were significantly smaller than the non-transgenic
controls (133, 134).
Project overview
Activated PKG, which is thought to be the main effector of cGMP, appears
to have cardiac anti-hypertrophic eftects, presumably through changes in
Ca2 handling and/or cytoskeletal arrangement. There is evidence that
PKG may play a role as weII in changing transcriptional patterns.
However, information about the effects 0f PKG and cGMP on gene
transcription is stiil minimal, In our laboratory, we have generated a
mouse that overexpresses in the heart the guanylyl cyclase domain of the
GC-A receptor, and have shown that these mice are protected from
experimentally induced hypertrophic stimuli. We have hypothesized that
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changes in expression at the transcriptional level in our GC-Transgenic
mouse would be one of the mechanisms that contributes to the this
protective effect. In order to investigate this question, we compared the
expression profile of cardiac genes in GC-Transgenic mice to that of their
wild-type (WT) littermates, using Affymetrix DNA arrays.
o
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Chapter 2:Materïal and Methods
Animais
Both animal modeis with gene inactivation (Nppa’ and lFNy) were
purchased from Jackson Laboratories (122, 135). The GC-Transgenic
animais were created in our lab as described (133). Ail mice are on a
C57BL/6 background. Animai procedures were approved by the IRCM
Animai Care Committee and conducted according to the
recommendations of the Canadian Council on Animal Care. In addition, ail
mice used in these experiments were kept in the SPF mouse facility.
Tissue coiiection
Animais were first killed by cervical dislocation and body weight was
measured when required, for example with the AAC. Atria were removed
and discarded whiie the heart was stiil beating. The ventricies were then
excised by cutting at the base of the heart, and dissected into their ieft
and right components (right ventricie was removed from the left ventricle).
The ieft ventricie inciudes the inter-ventricular septum. Left ventricles were
weighed separately from the right ventricles and quickly ftozen in Jiquid
nitrogen. Thymus, lung, liver, spleen, kidney and skeIetai muscle were
aiso removed, weighed and frozen in iiquid nitrogen. Tibia were removed
and kept on ice. Ail tissues were stored at —8OC with the exception of tibia
which were kept at 4°C.
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Extraction of total RNA from tissuesQ
RNA was prepared from tissues of male mice using a modified version of
the method described by Chomczynski et aI. (136, 137). Briefly, tissues
were first powdered in liquid nitrogen using a mortar and pestle, then
homogenized in 4 M guanidium-isothiocyanate, 25 mM sodium citrate,
0.5% N-Lauroylsarcosine, 0.7% 13 -mercaptoethanol using a Polytron
(Brinkmann instruments co.). RNA was extracted using 0.1 volume of 2 M
NaOAc, I volume of water (or citrate) saturated phenol, and 0.2 volume of
chlorophorm-isoamyl alcohol (49:1) followed by centrifugation at 10,000 x
g for 15 minutes. RNA in the supernatant was then precipitated with an
equal volume of isopropanol, followed by a second precipitation in 4 M
LiCl to improve the purity. Finally, RNA was extracted using an equal
volume of chloroform and precipitated in 100% ethanol and 0.1 volume of
3 M NaOAc overnight at —80CC. Total RNA was then redissolved in sterile
water and the concentration measured by spectrometry at 260/280À.
Small working aliquots of 20 pg were diiuted in sterile water ta 1 pg/pl for
future use. AIl RNA, stocks and working aliquots were kept at —80CC.
Affymetrix chip analysis
A total of 5 hybridizations were completed with total RNA samples from
the left ventricles of twa transgenic and three non-transgenic mice housed
in the SPF facility. Ail hybridizations were per[ormed on MGU74A
affymetrix chips which represented more than 12,000 mouse genes and
expressed sequence tags (ESTs). However, 3,000 probes representing
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ESTs from the IMAGE clone bank were faulty and were thus removed
from the analysis. Affymetrix chips are created using photolithographic
technology methods similar to the production of computer chips (138).
Affymetrix chips contain oligonucleotides (probes) of 25 base pairs in
length that are synthesized directly onto the surface of the chip. There are
two different types of probes, those that match the gene target sequence
exactly, known as the perfect match (PM), and partner probes whïch have
a single base pair mismatch in the middle of the probe, cailed the
mismatch probe (MM). Each gene is represented by a series of 11-20
probe pairs (PM and MM) known as a probe set. Intensity values for each
probe set were obtained from the Affymetrix MicroArray Suite (MAS) 5.0
software package. In order to define a measure cf expression that
represents the amount of mRNA for a corresponding gene, it is necessary
to summarize the intensities of the probes in each of the probe sets.
There are several different programs on the market designed to
accompiish this, including MAS, dChip and Robust Muiti-Array Analysis
(RMA). However, RMA has been shown to have better precision, with a
smaller standard deviation at ail levels 0f expression. In addition, RMA
has been shown to be more consistent in estimates of foid change (139).
Thus, resuits of the MAS analysis were then normalized using the RMA
p rog ram.
One problem with microarrays arises when performing statisticai analysis.
Due to the large quantity of data generated, it is difficuit for conventional
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statistical methods to be relevant given that even a p-value of 0.01, when
measuring J 0,000 genes, would identify 100 genes by chance. This
dilemma led to the development of Significance Analysis of Microarrays
program (SAM) (140). The SAM program computes a statistic for each
gene by measuring the strength of the relationship between the gene
expression and the standard deviation of repeated measurements for that
gene. At the same time, SAM uses repeated permutations of the data to
determine if the expression of any gene is significantly related to the
response. This allows to estimate of the number of genes that could be
found by chance which is given by the false discovery rate (FDR). Thus,
statistical analysis of the data was performed using SAM 1.10. SAM also
allows for the user to determine the cut-off of significance by adjusting the
parameter Delta, which allows the user to cut off the list at an FDR which
they are comfortable with. The analysed data were viewed and organized
using the Genespring 5.0 software package.
Northerns
Northerns were carried out according to (141).
Gel and transfer
5 pg aliquots (or 3 pg in the case of blots using samples from Nppa’
mice) were dehydrated using a Speed-vac (Savant) and redissolved in
0.065 pg/pL ethidium bromide, 0.01 M MOPS (Sigma), 10 mM NaOAc
and 1 mM EDTA. Samples were thon incubated at 65°C for 5 mm, and 5%
C, glycerol, 0.1 mM EDTA, 0.4% bromophenol blue and xylene cyanol were
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Q added before loading samples onto 1% agarose gel containing 6.16%deionized formaldehyde. Samples were migrated at either 65 V for 3
hours or 20 V overnight. Gels were then washed twice with sterile water
and 3 times in 1OX SSC (1.5 M NaCI and 1.65 M Na citrate). RNA in the
gel was subsequently transferred to a Gene Screen Plus membrane
(Perkin Elmer) overnight using JOX SSC. Membranes were washed with
2X SSC (0.3 M NaCI and 0.3 M NaCitrate) and baked 2 hours in a
vacuum oven at 80°C.
Probes
Two different types cf probes were used to probe RNA hybridized
membranes: some corresponded to inserts cut out from a plasmid
containing the cDNA, and others were prepared by RT-PCR amplification
of total RNA. For details on each probe please see table 2.1.
Gene Length of Source of Restriction Enzyme to
Probe probe remove insert
ANP (Rat) 750 bp Plasmid EcoRl/Hindlll
B2-Microglobulin(mouse) 405 bp PCR N/A
GC-Cat (Rat) 948 bp Plasmid BamHl/Hindlll
Table 2.1 Summary of probes used for Northern analysis
Amplification 0f a PCR fragment for the 2-microglobulin probe was
carried out under the following conditions: 1 pL of cDNA in H20 containing
0.5 pM forward (Fwd) and reverse (Rev) primers (Qiagen), 1.5 mM MgCI
(lnvitrogen), 0.2 mM denucleotides (Gibco), 0.5 units of Taq DNA
G
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Polymerase (Invitrogen) in PCR buffer minus Mg2 (Invitrogen) in a final
volume cf 20 pI. This PCR mixture was subjected to the following PCR
program carried eut on the MJ research PIC-225 Peltier thermocycler:
Initial denaturing for 2 minutes at 94°C, followed by 30 cycles of 30
seconds denaturing at 94°C, 30 seconds of annealing cf primers at 55°C,
and 30 seconds of elongation at 72°C and finally at the end of the cycles
10 minutes cf elongation at 72°C.
In the case cf probes originating from a plasmid, inserts were removed
from the plasmid using the appropriate restriction enzyme(s) (see table
2.1). Probes were then gel purified using the Concert gel purification kit
(Gibco) according te manufacturers instructions and the quality cf purified
product was verified on a second gel (142).
Labelling of probes
Labelling of the insert was achieved through incubation cf the denatured
insert with the following reaction mix at 37°C: 0.1 mM dAGTmix (dATP,
dGTP, dTTP each), 10 ng/pL random primer (Invitrogen), 50 pCi 32P
labelled dCTP (Amersham Biosciences), 9 units Large fragment DNA
polymerase (Invitrogen) in React2 buffer (Gibco). After incubation for 45
minutes at 37°C, 20 pCi 32P labelled dCTP were added and Ieft at 37°C for
an additional 15 min. Upon completion cf the second incubation, the
enzyme was denatured in 0.03 M EDTA at 65°C. Labelled probe was then
o
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purified via sequential ethanol precipitations until background was
significantiy diminished as verified by Geiger (surveyor 2000 Bicron).
Hybridization and washes
RNA bound membranes were prehybridized in 50% deionized formamide,
5X SSPE (0.75 M NaCI, 1.3 M NaH2PO4, and 12.6 M EDTA), 5X
Denhart’s solution, 1% SDS, and 0.2 mg/mL salmon sperm DNA for a
minimum of 8 hours. The amount of probe to be added to the hybridization
buffer (50% deionized formamide, 5X SSPE, 5X Denhart’s, 1% SDS, and
0.13 mg/mL salmon sperm DNA) corresponded to that necessary to yield
1x106 cpm/ml of final solution. The prehybridized membrane was then
incubated in the hybridization solution overnight at 42°C. Following
hybridization, membranes were washed twice with 2X SSC at room
temperature and several times in iX SSC (0.15 M NaCI, 0.17 M
NaCitrate) containing 1% SDS at increasing temperature, until the
background on the membrane, judged by Geiger, had diminished
significantly.
Exposure and analysis
Hybridized blots were exposed to a phosphor screen cassette and the
signais were visualized and quantified using ImageQuant 5.0 software
and normaiized to the intensity of the ethidium bromide-stained 28S
ribosomai band in each sampie.
o
35
O RT-PCR
Reverse transcription
RTs were carried out according to manufacturers instructions (Invitrogen).
Conditions used in the reverse transcription reactions for ail RT-PCRs in
this work are as foliows. 2 pg of RNA were denatured by incubation for 10
minutes at 65CC in the presence of 0.025 pglpL oligo dT (Invitrogen).
Denatured RNA was then transcribed in the presence 0f mM UNTP, 39
units RNAase Guard (Amersham Biosciences), and 200 units of
Superscript II enzyme (Invitrogen) in first-strand buffer (Invitrogen) at 42C
for one hour. The Superscript enzyme was then denatured at 7OC and
cDNA sampies kept at 4°C until further use.
PCR
Since ail PCRs were performed on cDNA, primers were designed to cross
over introns, thus avoiding any problems which may be caused by
possible DNA contamination of the RNA. This technique makes any
contaminating product difficuit to form and easy to visualize. PCR primers
were designed for the following genes: IFNy, proteosome subunit beta
type 8, T-ceII specific GTPase, tryptophanyl.tRNA synthetase, IFNy
induced GTPase and GAPDH (see table 2.2).
o
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Table 2.2 Summary of oligonucleotides used for PCR
Semi-quantitative PCRs
PCR reaction mix and programs
Optimal conditions for each primer set are reported in table 2.3. Each
PCR was performed on 1 pI of cDNA and amplification mixture was carried
out using 0.5 units 0f Taq DNA polymerase (lnvitrogen), in the presence
of PCR buffer minus Mg2 (Invitrogen), and 0.2 mM deoxynucleotides in a
final volume of 20 pI.
Optimal conditions for GAPDH were also determined and found to be in a
range that encompassed ail of the above conditions. Thus GAPDH PCRs
were performed under the conditions of the primer set in question.
Gene PCR Length Primer Sequence (5-3)
Name
f32-Microglobulin 391 bp Fwd CTTTCTGGTGCTTGTCTC
(mouse) Rev ATTGTATAGCATATTAGWC
IFNy (mouse) 472 bp Fwd CCTAGAGAAGACACATCAGC
Rev GAGCTCATTGAATGCTTGGC
Proteosome subunit beta 511 bp Fwd ACCACACTCGCCTTCAAGTT
type 8 (mouse) Rev GTGGTACATGTTGACGACTC
Tryptophanyl-tRNA 481 bp Fwd CCTAGAAGATGGCAGACATC
synthetase (mouse) Rev CTGTGTACAGGTAGAATGGC
Interferon-y induced 472 bp Fwd GAGAATTGAGACTGCCGTGA
GTPase (mouse) Rev TGGATACTCTGCAGTAGCTG
T-Cell specific GTPase 493 bp Fwd GTACTGAGAGACATCGAGAG
(mouse) Rev AGAGACTAGGAAGACTGGAG
GAPDH (rat) 404 bp Fwd TCCGCCCCTTCCGCTGATG
Rev CACGGAAGGCCATGCCAGTGA
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In order for the PCR to be semi-quantitative, it was pertinent that each
PCR for the use of quantitation be stopped during the linear growth phase
of the PCR reaction. Furthermore, it is preferable to then transfer the PCR
product to a membrane using southern techniques so that the PCR
products can be probed with a radioactively labelled probe which allows a
greater sensitivity than visualization with ethidium bromide. Thus, PCRs
were first performed at a range of cycle numbers and the optimal cycle
number for quantification determined (also shown in table 2.3) and then
probed in the same fashion as a southern (143).
Primer set Primers Fwd MgCI2 Annealing Cycle
and Rev temp (°C) num ber
Proteosome subunit beta type 8 5 pM 2.0 mM 61.6 23
Tryptophanyl-tRNA synthetase 5 pM 2.0 mM 61.6 23
Interferon-y induced GTPase 5 pM 2.0 mM 61.6 23
T-Cell specific GTPase 5 pM 2.0 mM 61.6 23
IFNy 5 pM 1.5 mM 55 27
Table 2.3.Summary cf PCR programs
Gel electrophoresis and transfer to nylon membrane
PCR products were resolved on a 1.5% agarose gel. The gel was then
washed twice in 0.5 M NaOH and transferred to a Gene Screen Plus
membrane (Perkin Elmer) overnight using 1OX SSC.
Probes for analysis by southern
Details on oligomers used for probing membranes can be found in table
2.4. Probes for Southern analyses consisted of a 2Omer oligonucleotide
C
3$
O
specific for each PCR product. Probes were labelled with 50 jiCi of 32P-
ydATP using 6.6 pM oligomer in Forward buffer (Invitrogen) in the
presence cf T4 Kinase (Invitrogen) enzyme. Labelled oligomers were
purified using the ProbeQuant Kit (Amersham).
Hybridization and washes
Membranes were prehybridized in 6X SSC (0.9 M NaCI, 1 M NaCitrate),
20 mM NaH2PO4, 0.4% SDS, 5X Denhardt’s and 900 jig/mL of salmon
sperm DNA for a minimum of 8 hours. Labelled probe was hybridized to
the membrane overnight at 42°C at a concentration 0f I million counts/mI
0f sperm DNA. The following morning, hybridized membranes were
washed multiple times in iX SSC and 1% SDS at gradually increasing
temperatures until there was Iittle detection of background.
Gene Sequence 5’ to 3’ Length
IFNy AGCTCTTCCTCATGGCTGTT 20 bp
Proteosome subunit CAACATGATGCTGCAGTACC 20 bp
beta type 8
Tryptophanyl-tRNA AAAGGCATCGACTATGACAAGC 22 bp
synthetase
Interferon-y induced CTCATCGGACACGAAGAGAA 20 bp
GTPase
T-CeII specific GTPase GACCACTAACTTCACACCAC 20 bp
GAPDH CCACAGTCCATGCCATCACT 20 bp
Figure 2.4 Summary of probes used in Semi-quantitative RT-PCR (Southern)
analysis
o
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Exposure and analysis
n
Hybridized membranes were first exposed to a phosphor screen cassette
(molecular dynamics, sunnydale, CA.) and then to X-OMAT AR film
(Kodak) if the signal was weak. Visualization cf the phosphor screen and
quantification were achieved though the ImageQuant software and each
gene was normalized to the intensity cf the GAPDH PCR products of the
same cDNA performed at the same time and under the same conditions.
Abdominal aortic constrictions
LVH was induced in male mice by surgical introduction of an abdominal
aortic constriction (AAC) (133). Mice were first weighed and anesthetized
via intramuscular injection of 1 pI per gram of an anaesthetic cocktail
(0.04% AC promazine and 4% Ketamine in 0.9% sterile saline). A blunted
26-gauge needle was positioned on top of the abdominal aorta (rostrally
to the renal arteries), a suture was placed around both the needle and the
aorta with a 6-0 nylon string, and the needle was subsequently withdrawn.
Before closing the incision the abdominal cavity was flooded with 1 mL of
sterile saline. Mice were also injected 1 ml of sterile 10% sucrose
subcutaneously following the surgery. Sham surgeries were conducted in
a similar manner, with the exception that no suture was tied around the
aorta.
o
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Chapter 3: Results
Comparison of overali changes in gene expression
Affymetrix chip resuits
Initial comparison of RNA expression levels in transgenic compared with
wild-type myccardium revealed 41 genes with an increase in expression
in the GC-Transgenic mice of two fold or more (figure 3.1). There were,
however, no genes that were found to be down regulated to this
magnitude. Surprisingly, ail but three of these genes were found to be
well-known targets of the pro-inflammatory cytokine Interferon-y (IFNy)
(Table 3.1). IFNy is normally secreted by thymus derived T-lymphocytes
(144) and is involved in the regulation cf several aspects cf the immune
function. Many of the classes of IFNy-regulated genes were found in the
GC-Transgenic mice (Table 3.1).
Figure 3.1. Changes in gene
expression observed in CG
Transgenic mice relative te WT
mice via Affymetrix technology.
RNA from Left ventricles (LV) cf
GC-Transgenic (TG) and wild type
(WT) mice were hybridized to
mgU74A affymetrix chips. The
normalized signal intensities from
the hybridizations of GC-transgenic
mice were plotted against those of
the WT mice. Red dots represent
individual genes. The two outer
Green unes represent 2 fold
thresholds whereas the centre
green une represents equal
amounts of a specific transcripts in
both TG and WT.
L38444 TceII specific GTPase 6 8,8
AJ007972 IfNy induced GTPase 6 7,5
M27134 Histocompatibility 2, D region locus 1 6 6,0
X00246 Proteosome subunit, beta type 8 6 5,4
U22033 ATP-binding cassette, sub-family B memb. 2 6 3,7
M35247 Ia-associated invariant chain 6 3,6
X01838 Proteosome subunit, beta type 9 6 3,4
V00746 Histocompatibility 2, T region locus 23 6 3,2
X00496 Histocompatibility 2, class li antigen A, alpha 6 3,1
X58609 Mouse Q4 class I MHC gene 6 3,1
U60020 Histocompatibility 2, L region 6 3,0
M18837 Histocompatibility 2, T region Iocus 10 6 2,8
M69069 Histocompatibility 2, class Il antigen E beta 6 2,2
D44456 Ub83g12.rl Mus musculus cDNA 6 2,7
X52643 Mouse Q819d gene 6 2,3
X16202 Histocompatibility 2, K region locus 2 8 5,8
X52490 Beta-2 microglobulin 8 3,8
M21065 Histocompatibility 2, K region 8 3,7
Y00629 Histocompatibility 2, Q region locus 2 8 3,5
AJ007970 Histocompatibility 2, D region locus 1 8 3,5
M34815 Proteasome subunit, beta type 10 8 2,1
M58156 Histocompatibility 2, T region locus 17 14 3,8
M35244 Lymphocyte antigen 6 complex 14 2,2
Al117211 Tryptophanyl-tRNAsynthetase 14 2,6
M27034 Tryptophanyl-tRNA synthetase 14 2,1
M22531 MHC class I Q4 beta-2-microglobulin fQb-1) 18 3,4
X69656 MHC class I D-region ceil surface antigen 18 2,7
M64085 Complement component 1, q subcomponent, alpha 18 2 1polypeptide
X04653 Erythroid differentiation regulator 18 2,1
D90146 Interferon regulatory factor 1 19 3,0
Y10875 Cathepsin S 19 2,2
X00958 Intercellularadhesion molecule 19 2,1
AJ007909 IFNy inducible protein, 47 kDa 32 2,8
X58861 Complement component 1, q subcomponent, beta 32 2,5polypeptide
A1851163 Guanylate nucleotide binding protein 2 35 3,6
M63630 Ua19f08.rl Mus musculus cDNA 38 2,1
AJ223208 Small inducible cytokine B subfamily, member 9 44 3,5
false Discovery
FoldAccession Gene description Class of IFNy target FDR
change
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MHC class I
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Other
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Other
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Table 3.1 Table oftwo fold upregulated genes ftom the Affymetrix analysis. FDR
Rate
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Verification of affymetrix resuits
Because the upregulation of pro-inflammatory cytokine target genes was
unexpected, and microarrays analyses tend to be complicated by the
frequent occurrence of false positives, results were further analyzed both
statistically and experimentally.
SAM analysis
SAM analysis of the RMA normalized data revealed 119 significant genes
at an arbitrary delta of 0.18922. AIl but 3 0f the 2 fold upregulated genes
were considered significant by SAM at this delta setting. Thus, 38 genes
were significantly upregulated 2 fold, 36 of them being IFNy targets.
However, the FDR given by the SAM program provides more useful
information. 0f the genes that were considered both significant and
upregulated 2 fold, 15 had a FDR of 6% meaning that 6 % of the genes
named could be false positives. 45 genes are under 20% and only 5 are
above 30% (Table 3.1).
Confirmations by northern analysis
In an effort to solidly confirm the upregulation 0f the genes present on the
list, 32-microglobuIin (r32m) levels were analyzed using Northern analysis.
This confirmed that 32m is upregulated in the GC-Transgenic with a fold
change of 3.6 (Figure 3.2A), similar to the predicted fold change (Table
3.1). We did observe, however, thatthe fold change in the northern results
C’ were dependant on the animal unit which the mice resided in. Our mice
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were kept in two different animal units, one ‘clean’ (SPF) and the other
‘dirty’ (conventional). Ail animais are born in the SPF, and due to space
restrictions, they are often transferred to the conventional unit until further
use. We discovered that animais from the SPF gave a fold change ratio
A. B.
Nppa gene:
F2M
28s
* DffJ
•IG
o.JLli Ï
Left Spleen Kidney Liver Skeletai
ventricle muscle
+1+ -1-
— *
Figure 3.2. Biological verification of Affymetrix gene chip with 32-Microglcbulin.
(A) Ncrthern Anaiysis cf f32-Microgicbulin (132M) expression in the Left Ventricies
(LV) cf GC-Transgenic (TG) and wiid-type (WT) mice.(B) Resuits cf Ncrthern
analyses showing relative expression cf j32-Micrcglcbuiin in LV as weII as other
tissues cf the GC-Transgenic versus the WT mice. Values were ncrmalized te
that cf the 28s ribosomal RNA (28s) and expressed as fcld increase compared to
WT LV. Bars represent mean ± S.E. (n= 5 for each group) (C) Ncrthern analysis
cf 32-Microglcbulin expression in LV cf Nppa KO mice versus WT mice. The 28s
ribcscmal DNA was used as a Icading ccntrol in ail cases.
for 132m that was doser to that estimated on the chip than the animais
from the conventional, which had increased baseline levels cf 132M (data
flot shown). This is likely due a higher level cf pathogens present in the
o
32M
TG WT
(“3
C,’
C.
conventional mouse unit. Given this information, ail cf the verifications
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were completed using mice that came directly from the SPF. It should also
be noted that the mice used for the Affymetrix analysis were also kept in
the SPF.
Confirmation by RT-PCR
In addition, semi-quantitative RT-PCRs were performed on four other
genes that showed a 2-fold significant increase in expression (1-ceil
specific GTPase, IFNy-induced GTPase, Proteosome (prosome,
macropain) subunit beta type 9, Tryptophanyl-tRNA synthetase). Resuits
reveaied that ail candidate genes were upregulated, although not aiways
at the expected ratio (Table 3.2). A possible explanation for this is that
gene expression is estimated based on a set of probes, representing one
gene, which do not hybridize with the mRNA as uniformly as in theory.
Thus, given that data needs to be normalized and averaged for each
probe set, it is reasonable to assume that this intensity value may deviate
from the actual number as measured by northern/RT-PCR. AIl of the fold
changes in the RT-PCRs were significant using the two tailed student test
(p-value < 0.05) (Table 3.2).
Gene Description Fold Induction
Affymetrix Experimental
T gtp T-ceII specific GIPase 8.8 3.2a
Gtpi-pending lFN’-induced GTPase 7.5 2.2a
Psmb9 Proteosome subunit, beta 3.4 1.5a
type 9
Wars Tryptophanyl-tRNA 2.6 1 .6a
synthetase
Table 3.2 Summary of semi-quantitative RT-PCR results for biological
verifications of Affymetrix chip experiment. ap<005G
45
Upregulation in expression is heart specific
Because the CC transgene is limited to cardiac tissue, the changes in
IFNy target genes observed here should be restricted to the heart. Levels
of 132m were thus investigated in spleen, kidney, muscle and liver. As
seen in figure 3.2B, 132m is upregulated in the heart tissue and flot in any
cf the other tissues that were investigated, indicating that the expression
of IFNy targets is dependent on the transgene expression.
Nppa KO mice have Iower2m levels in LV
To reinforce the notion that the GC transgene has an effect on IFNy
targets, we looked at the level of expression of 132m in the hearts cf Nppa
KO mice. These mice do not produce any ANP, the peptide that activates
the GC-A, and should therefore have no ANP-dependent GC activity. As
shown in Figure 3.2C, Nppa KO mice had lower expression of 132m than
their WT littermates.
Upregulation of IFNy in the GC-Transgenic mice
The above results indicate that the presence of the GC transgene leads to
an increase in the expression of IFNy-regulated genes. Analysis of the
Affymetrix data revealed that IFNy was on the MG-U74A chip, but that its
corresponding hybridization signal was below the threshold of detection.
This is likely due to the fact that cytokines are tightly regulated molecules
normally expressed at low levels in the organism. A second pro
inflammatory cytokine that can modulate the expression of many of the
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genes upregulated in the GC-Transgenic, INFo, was also expressed
below detection levels. As IFNy is thought to be the major regulator of the
genes found on the chip, the level of expression 0f IFNy in the TG mice
was compared with that 0f their non-transgenic littermates using semi
quantitative RT-PCR. This procedure revealed a 3.8 fold increase in IFNy
expression in the TG mice (Figure 3.3). This confirmed that IFN7 is
upregulated in the GC-Transgenic and indicates that this pro-inflammatory
cytokine might orchestrate the observed upregulation of immune-related
genes.
A.
B.
TG WT
IFNy H
GAPDH —
500
400
300
200
100
o
Figure 3.3. Expression cf IFNy
in GC-Iransgenic mice. (A)
Semi-quantitative RT-PCR
was performed on Ieft
ventricles (LV) cf the GC
Transgenic (TG) and wild
type (WT) mice using primers
specific for IFNy and GAPDH
(as a loading ccntrol) (B)
Quantification cf IFNy found in
LV cf 1G versus WT
ncrmalized te GAPDH. Bats
represent mean ± S.E. (n8
for each group)
Wf TG
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Role of IFNy in tesponse to hypertrophic stimuli
Abdominal aortic constrictions of IENyKO mice
Based on the above data, we postulated that IFNy may confer at least part
of the protective properties of the TG mice. To test this hypothesis, a
series cf AACs on IFNy KO male mice were catried out and compared
with non-transgenic age-matched male mice on the same background
(C57/B6). As pro-inflammatory cytokines are induced rapidly following
environmental stresses (145), the progression of the hypertrophic
response was followed more thoroughly using early time points. Some
mice lost weight immediately after the surgery, thus making traditional
measurement ratios involving bodyweight less reliable at the two day time
point (data not shown). We therefore compared the weight cf various
organs to that cf the tibia length which was unlikely to change dramatically
over the course of the study.
The initial increase of LV weight following AAC of non-transgenic and
IFNy KO mice was similar (Figure 3.4A). Nevertheless, there was a
significant reduction in LV weight of IFNy KO mice between 14 and 21
days while the LV weightltibia length ratio of WT, which are in accordance
with previously published results (174, 175), remained constant. The
difference between LV/tibia ratio of non-transgenic and IFNy KO mice was
however not statistically significant at 21 days post AAC (p-value = 0.067).
Other markers of cardiac dysfunction, namely right ventricle (RV) and lung
4$
weight were also evaluated. No other cardiac dysfunction was observed,
as no change was apparent in these parameters throughout the time
course (Table 3.3 and data flot shown).
Experimental group WT IFNy KO
Sham MC Sham MC
LV/Tibia 4.43±0.25 6.50±0.36a 4.68±0.24 5.75±0.15a
RVrribia 1.41±0.08 1.59±0.11 1.36±0.12 1.49±0.05
Lung/Tibia 9.11±0.09 9.61±0.36 8.89±0.26 9.31±0.25
Table 3.3 .Tissue weight to tibia length ratios at 3 weeks. Shown are
mean ± SE. (n = 3-7 per group). LV, Left ventricle RV, right ventricle
AAC, Abdominal Aortic Constriction. ap.<0 05 for MC versus sham group
o
ANP expression in the left ventricles of IFNy KO with abdominal aortic
constrictions
Given that there was a decrease in LV weightltibia Iength ratio cf IFN’y KO
mice after the initial hypertrophic response, we evaluated the level of ANP
mRNA in the left ventricles of both non-transgenic and IFNy mice folJowing
AAC. Probed membranes containing RNA from the 2 day, 2 week and 3
week time points were hybridized using a probe for ANP peptide. The
levels of ANP initially rose dramatically upon the AAC in both IFNy KO
and WT mice (Figure 3.4B). However, ANP levels then decreased
gradually and in a linear fashion in WT mice, while that of the IFNy KO
continued to rise, becoming significantly higher than that of the ‘NT mice
by 21 days post AAC.
oFigure 3.4. LV size and expression of ANP following Abdominal Aortic
Constrictions (AAC) of WT and IFNy mice. (A) Mice were sacrificed at the
indicated times after surgery and Left Ventricle (LV) weight to tibial length
ratios were plotted. Bars represent mean ± S.E (n= 5-8 per group) (B) Relative
amounts of ANP in the LV of IFN7 KO and WT AAC mice by northern analysis
using a probe against ANP. Shown are mean ± S.E. (n=3-7 per group). *
0.05
o
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Chapter 4: Discussion
The GC-Transgenic mice have a constitutively active guanylyl-cyclase
activity in their cardiomyocytes, correlated with an increased amount cf
cytosolic cGMP (133). These mice are protected from experimentally
induced hypertrophy, thereby making them a good model to study the
anti-hypertrophic effects cf ANP and its downstream effector cGMP. As
this might be achieved, at least in part, through the influence of PKG on
gene transcription (117), we compared gene expression levels of GC
Transgenic mice and WT mice under basal conditions using affymetrix
technology. Affymetrix chips have been on the market for a number 0f
years, and are highly accepted manner cf scanning large numbers of
genes for differences in expression levels of RNA species. The results
were unexpected in two ways: there were minimal changes in gene
expression (<50 genes changed two fold or more) and most of the
upregulated genes were IFNy target genes.
Affymetrix resuits
Changes in gene expression
Affymetrix experiments typically generate a list of several hundred genes
whose expression vary two fold or more. This is at odds with what was
found with the GC-Transgenic mice. In addition, no changes in genes
involved in heart function or hypertrophy were observed in the absence of
hemodynamic stimuli. It is thus possible that the ANP-activated cGMP
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Q pathway has littie effect on gene expression in absence of stimulus. Thisis in une with the fact that the hearts cf GC-Transgenic mice and their WT
littermates can be functionaiiy distinguished only foliowing an hypertrophic
stimulus (133). It is thus possible that ANP does not activate genes, but
rather inhibits the activation of hypertrophic genes when these stimuli are
added to the ceils. lndeed, with the exception of TNFŒ, ail cardiac genes
whose transcription had previously been reported to be repressed by
cGMP were identified in conditions were hypertrophic stimuli were
operating (reviewed in (117)). in particular, genes that are known
biomarkers of hypertrophy have been shown to be downregulated by
cGMP under such conditions. One way this could be achieved is through
the modulation cf Ca2 signais by cGMP, which antagonize the increase in
contractiiity as well as the Ca2-dependent changes in transcription
induced by hypertrophic stimuli (15, 41). Analysis of gene expression
following AAC of GC-Transgenic mice might thus prove informative.
Targets of IFN7
As mentioned above, one of the oniy genes known te be upregulated by
cGMP in the heart under unstimulated circumstances is the pro
inflammatory cytokine TNFG. Likewise, virtuaiiy ail of the genes
upregulated in the CG-Transgenic mice are targets of a second pro
inflammatory cytokine, IFNy, which was aise upreguiated. 0f note, as this
expression is specific to the heart of the GC-Transgenic and f32-
microglobuiin is decreased in the LV of Nppa KO mice (Figure 3.2),
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expression of IFN7 and its targets are unlikely to be the resuit of an
aberrant insertion effect. lndeed, two other mouse models of heart
protection from stress were found to have upregulation of IFNy or some of
its targets (146, 147). Therefore, several conditions providing protection
against stress lead to increased levels of pro-inflammatory cytokines.
TNFa plays a major role in innate immunity by activating both apoptosis,
through DISC formation (148), and the pro-inflammatory transcription
factor NE-KB (149). On the other hand, IFNy is a mediator of both innate
and adaptive immunity (150). CeIlular functions mediated by IFNy include
stimulation of bactericidal activity of phagocytes, stimulation of antigen
presentation through class I and class li major histocompatibiiity
complexes (MHC) and direction of leukocyte-endothelium interactions
(151, 152). IFNy aiso affects cellular activities such as proliferation and
apoptosis (150). Thus, these two cytokines have similar but distinct
functions. As the genes upregulated in the GC-Transgenic more closely
matched that of IFNy targets, the biological relevance of pro-inflammatory
cytokines in hypertrophy was thus studied using lFNy and not TNFa.
Pro-inflammatory cytokines in the heart
Maladaptive responses
Cytokines play a pivotai role in the regulation of various biological
responses such as immune responses and inflammation. They serve as a
primary aiarm to alert the immune system and to direct it to that particular
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area of the organism (153). However, if cytokïne signalling persists or is
exaggerated, it can lead to inappropriate tissue damage and destruction.
Example of such diseases include rheumatoid arthritis, inflammatory
bowel disease and septic shock (153). In the heart, several cytokines
such as leukemia inhibitory factor, cardiotropin and TNFa have been
found to induce hypertrophic growth, cardiac remodelling, and changes in
contractility of cardiomyocytes (reviewed in (154)). For example, TNFa is
sufficient to provoke hypertrophic growth in cardiomyocytes (155), causes
the degradation and remodeiling of the extracellular matrix (ECM) (156)
and decreases LV ejection performance (157). High doses of TNFa also
cause hypotension and septic shock. (158). Detrimental effects of pro
inflammatory cytokines in the heart include LV dysfunction, puimonary
oedema, cardiomyopathy, LV remodelling, as well as changes in both
myocardial metabolism and mitochondrial energetics (159).
Protective responses
Not ail effects of pro-inflammatory cytokines are though to be detrimental.
A new theory emerging from Douglas Mann’s group, states that the heart
uses pro-inflammatory cytokines to adapt to environmental stresses (159).
This theory suggests that pro-infiammatory cytokines are the heart’s
immediate alarm signais which initiate hypertrophic growth, myocardial
cytoprotective responses and tissue repair. This initiai expression of pro
inflammatory cytokines would thus have a beneficial effect as the heart
becomes better capable of dealing with a greater load, tissue injury is
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Iimited, and repair cf the damage is initiated. Howevet, if the expression of
these cytokines becomes deregulated or constitutive, they will have
destructive effects on cardiac tissue and function.
Support for this theory is found in the fact that pro-inflammatory cytokines
are not expressed constitutively in the heart but rather immediately upon
different types of myocardial injury (159, 160). Also, a number cf Ïfl vitro
and ex vivo experiments have shown that pre-treatment of cardiac ceils
with cytokines can protect them from environmental insuits such as
ischemia (161-163). Finally, the most convincing evidence cornes from
loss of function studies of GP13O and the double KO of the TNFa
receptors (TNFR1 and TNFR2). In the case cf CPi 30 (receptor for the 1L6
farnily of cytokines), the KO mice die before birth Iargely due to
developrnental abnormalities of the heart (164). On the other hand, the
heart specific GP13O KO mice survive and are normal under basal
conditions but have decreased survival, ventricular enlargement and
increased cardiomyocyte apoptosis when given a stress such as TAC
(165). Mice lacking both TNF receptors are also normal under unstressed
conditions but have increased infarct size and myocyte apoptosis
following experimentally induced injury (166). This evidence strongly
suggests that the role cf these receptors is beneficial in response to
environmental stresses. Pro-inflammatory cytokines are proposed to exert
their protection through an increase in activity of the transcription factor
NF-KB, leading to the upregulation of cytoprotective proteins such as
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MnSOD (a free radical scavenger), HSPs, and various inhibitors of
apoptosis (167-169).
IFN7 and hypertrophy
Considering that close Iinks between TNFa and IFNy signalling have
already been weII established (150), the increase in IFNy target genes
observed in the GC-Transgenic mice could be part of the protective
function of pro-inflammatory cytokines in the heart. To test this possibility,
we performed AAC in IFNy’ mice, and examined whether the ensuing
cardiac hypertrophy had characteristics that were different from that of WT
counterparts. lnterestingly, ANP levels were significantly higher in the
IFNy KO mice than the WT mice 21 days post AAC. As ANP is considered
one of the most reliable biomarkers of hypertrophy (10), this could indicate
that these mice will develop hypertrophy at later time points. However,
none of the other parameters studied hint at such a trend. In fact, although
there is no statistical difference between LV/tibia ratios of IFNy KO and
WT mice at 21 days post AAC, the LV/tibia ratio of IFNy mice was Iower at
21 days post AAC than at 14 days post-AAC. In addition, within the time
frame 0f the experiment, there was no sign of cardiac decompensation
(which could manifest itself by increases in the ratios of RV/tibia and
Iung/tibia) through the course of the study.
As with INF, KO models of IFNy, its receptor (IFNyR) or its main
() transcription factor (STAT1) have no reported defects in heart appearance
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and function under basal conditions (135, 170-J 72). However, whiie TNF
KO models have exaggerated hypertrophy following stress (166), IFNy KO
mice do not, at least in the case of AAC (Figure 3.4). Thus, IFNy may not
have protective effect such as that driven by TNFa. Rather, as IFNy KO
mice have elevated LV concentrations of ANP, IFNy seems to be piaying
a negative regulatory role on ANP. Since ANP is anti-hypertrophic, this
wouid explain why the hearts of the IFNy KO decreased in size between
14 and 21 days.
Origin ofIFNy
The affymetrix analysis was carried out using LV tissue, which s a mixture
of celis including fibroblasts, cardiomyocytes and possibly immune cells.
As IFNy is thought to be produced mainly by NK and T celis, it is possible
that the induction 0f IFNy targets in the GC-Transgenic results from an
infiltration 0f immune celis into the cardiac tissue of these mice. On the
other hand, ail nucleated heart ceil types have been shown to produce
severai cytokines that were originally considered to be solely produced by
ceils 0f the immune system (145, 173). It is thus possible that the
cardiomyocytes themselves are producing IFNy. In either case, as the net
effect of IFNy is to promote a macrophage-rich inflammatory reaction, this
could Iead to a recruitment 0f macrophages by cardiomyocytes. Activating
this pathway for a short term could thus be beneficial for heart function, as
suggested for other pro-inflammatory cytokines (159).
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However, since experimentally induced hypertrophy is accompanied by
increases in ventricular ANP concentration, it is likely that this condition
also leads to long term induction of IFNy, as is observed in the GC
Transgenic. On the one hand, this could lead to deleterious
consequences for heart function (159). On the other hand, the GC
transgenic, which has increased IFNy, is protected against experimentally
induced hypertrophy. One possibility is that induction of IFNy by ANP is
not directly linked to its Iong-term anti-hypertrophic effect, which likely
depends on calcium signalling (see above). Given that the outcome of
cardiac stress presented here (figure 3.4) differ from what has previously
been reported in TNFa KO mice (166) and that IFNy and TNFa have
distinct roles in immune function, it is also possible that the role of TNFa
and IFNy are different following cardiac injury. However, as the difference
in heart size between WT and IFNy mice following AAC are rather subtle,
further experiments are required to shed light on the role of IFN7 in
response to hypertroph ic stresses.
o
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General conclusions
The GC-Transgenic mouse provides a useful tool to study the role of the
ANP signalling pathway in the protection against hypertrophy. Analysis of
changes in genes transcription revealed that IFNy and its targets are
increased in the GC-Transgenic mice. Subsequent investigations
comparing the responses of IFNy deficient mice to that of their wild-type
counterparts in following AAC revealed subtle differences in the changes
in ventricular size and ANP concentration, but do not support the
hypothesis that IFNy plays an important part in the anti-hypertrophic effect
of cGMP. However, since other findings indicate that pro-inflammatory
cytokines may play important roles in the modulation of cardiac stress
responses (155, 161-163, 165, 166), it remains possible that lFNywiII play
other cardioprotective roles. Future studies wiIl be necessary to determine
whether the cGMP-induced upregulation 0f cardiac IFNy will be sufficient
to play a role in these other conditions.
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